Sign in
4

Changes in Ownership

MoonLake Immunotherapeutics Filed Acc 0001213900-26-055799

Chief Financial Officer sold 13,653 shares at $20.02 ($273,333)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Bodenstedt Matthias · Chief Financial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-05-11 Sale : show line 1 in the form 10b5-1 −13,653 $20.02 $273,333 1,172,431 D
Open-market sales · 13,653 sh · avg $20.02 · $273,333
Loading xslF345X06/ownership.xml…